Kaplan Fox is Investigating Claims on Behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors for Potential Securities Law Violations
Law firm Kaplan Fox is investigating Madrigal Pharmaceuticals for potential securities violations following a whistleblower complaint filed by a former employee alleging retaliation under Sarbanes-Oxley Act provisions. The complaint concerns data and reporting practices. Madrigal's stock declined 8.08% on November 3, 2026, following the disclosure in the company's Form 10-Q filing.